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Abstract A novel single-step microbial transformation process for the efficient production of
carthamidin and isocarthamidin from naringenin by yeast Rhodotorula marina in an aerated
bioreactor was described. The biotransformation led to the total product concentration of
233 mg/l. The highest conversion efficiency observed for carthamidin was 0.31 mg/mg of
naringenin and for isocarthamidin 0.47 mg/mg of naringenin.
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Introduction
Flavonoids are polyphenolic compounds of plant origin that are important constituents of the
human diet. They have been reported to possess a wide spectrum of health-promoting
properties, including antibacterial, antiviral, estrogenic, anti-obesity, and anticancer activities,
which are useful in the treatment of several human pathologies [1].
Naringenin (Fig. 1) is one of the most abundant flavonoids found in grapes, tomatoes, and
citrus fruits. This flavanone has gained increasing interest in recent years because of its wide
range of biological activity, including antioxidant [2], anti-inflammatory [3], antimicrobial
[4, 5], antiviral [6], antimutagenic [7], antiestrogenic [8], antiatherogenic [9], hepatoprotective
[10, 11], nephroprotective [12], and anticancer [13, 14] action. Positive effects of naringenin
on lipid metabolism [15, 16] and plasma glucose levels [16–19] have also been reported.
Since naringenin is a compound isolated from the agro-residue, it is relatively inexpensive. Not
only does it serve as an excellent and frequently employed model flavonoid but also it is a leading
substance for the preparation of new biologically active derivatives. For this purpose both chemical
and biotransformation methods have been used. Chemical modifications involved acylation [20]
and O-alkylation [20, 21] while biotransformations using microorganisms, plant cultured cells, and
pure enzymes led to glycosylation [22], O-alkylation [23], acylation [24], halogenation [25],
sulfation [26, 27], C–C coupling [28], and hydroxylation [29–32].
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The last of these modifications, conducted by the fungi of the genus Aspergillus, afforded
carthamidin (6-hydroxynaringenin) and isocarthamidin (8-hydroxynaringenin). These metab-
olites exhibited much stronger antioxidant activity than both naringenin and its glycoside
naringin [29]. The activity of the isocarthamidin is comparable to that of α-tocopherol,
whereas carthamidin is slightly less active. Kim et al. [33] suggested that these compounds
obtained by fermentation of Dangyuja (Citrus grandis Osbeck) extract increased also the
antidiabetic activity of the raw material used. A novel antidiabetic agent which contains
carthamidine and/or isocarthamidin as active ingredients was also patented [34].
Recently, 8-hydroxynaringenin has been identified as a suicide substrate of mushroom
tyrosinase [35], which greatly expands the range of its possible applications. Tyrosinase is a
monooxygenase known to be the key enzyme in melanin biosynthesis, by catalyzing the
oxidation of phenol to O-chinone, observed in the early stage of various browning phenomena
in nature [36, 37]. Tyrosinase inhibitors can therefore be useful for the control of enzymatic
browning during fruit and vegetable pulp manufacturing [38], for the treatment of some derma-
tological disorders associated with melanin hyperpigmentation [39] and neurodegeneration
[40, 41], for whitening and depigmentation in cosmetics [42, 43], and for insect control [44].
For the above reasons and because of low content of carthamidin and isocarthamidin in
plant material [45–48], it is desirable to develop effective methods of obtaining carthamidin
and isocarthamidin from naringenin. Biotransformation is a method that allows for regiose-
lective hydroxylation of the substrate and, at the same time, preserves the status of the products
as “natural compounds.” Therefore, it is particularly useful in this respect.
This paper describes biotransformation leading to carthamidin and isocarthamidin, carried
out on a preparative scale and using yeast as a biocatalyst.
Materials and Methods
Microorganism
The yeast strain Rhodotorula marina AM77 was purchased from Institute of Biology and
Botany of the Wrocław Medical University, Poland.
Substrate
Naringenin was purchased from Sigma-Aldrich.
Products
Carthamidin (5, 6, 7, 4′- tetrahydroxyflavanone) 1H NMR (600 MHz, DMSO-d6) δ (ppm):
2.65 (dd, 1H, J=17.1; 3.0 Hz, H-3 eq); 3.22 (dd, 1H, J=17.1; 12.3 Hz, H-3ax); 5.36 (dd, 1H,

























Fig. 1 Transformation of naringenin by Rhodotorula marina
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J=8.6 Hz, H-2′,6′); 8.11 (s, 1H, 7–OH); 9.57 (s, 1H, 4′–OH); 10.42 (s, 1H, 6-OH); 11.98
(s, 1H, 5-OH). 13C NMR (DMSO-d6) δ (ppm): 42.32 (C-3); 78.50 (C-2); 94.73 (C-8); 101.71
(C-10); 115.16 (C-3′, 5′); 126.32 (C-6); 128.30 (C-2′, 6′); 129.19 (C-1′); 150.19 (C-9); 155.27
(C-5); 155.77 (C-7); 157.65 (C-4′); 196.66 (C-4). HR ESI-MS m/z: 287.0520 [M–H]− (calcd
for C15H12O6–H, 287.0556); UV (MeOH) λmax 292.7 nm.
Isocarthamidim (5, 7, 8, 4′- tetrahydroxyflavanone) 1H NMR (600 MHz, DMSO-d6) δ
(ppm): 2.71 (dd, 1H, J=17.1; 3.1 Hz, H-3 eq); 3.22 (dd, 1H, J=17.1; 12.3 Hz, H-3ax); 5.42
(dd, 1H, J=12.3; 2.9 Hz, H-2); 5.93 (s, 1H, H-6); 6.79 (d, 2H, J=8.5 Hz, H-3′, 5′); 7.35 (d, 2H,
J=8.5 Hz, H-2′, 6′); 8.11 (s, 1H, 7-OH); 9.57 (s, 1H, 4′-OH); 10.42 (s, 1H, 8-OH); 11.75
(s, 1H, 5-OH). 13C NMR (DMSO-d6) δ (ppm): 42.28 (C-3); 78.50 (C-2); 95.44 (C-6); 101.71
(C-10); 115.12 (C-3′,5′); 125.61 (C-8); 128.40 (C-2′, 6′); 129.19 (C-1′); 149.41 (C-9); 156.51
(C-5); 155.81 (C-7); 157.65 (C-4′); 196.62 (C-4). HR ESI-MS m/z: 287.05200 [M-H]−
(calcd for C15H12O6–H, 287.0556); UV (MeOH) λmax 293.9 nm.
Biotransformation Procedure
The growth medium for inoculum preparation and for biotransformation process (Sabouraud
medium) contained 3 % glucose and 1 % bacto peptone (Difco). A seed culture was grown in a
six 300-ml flasks (each containing 50ml of the growthmedium) on a shaker at 28 °C for 2 days to
obtain the cell dry weight of ca. 7 g/L. The inoculum in amount of 300 ml was introduced into a
5-l fermenter (Biostat B Plus, Sartorius, Germany), containing 1.7 l of the medium. After 24 h of
cultivation at 28 °C, 600 mg of naringenin dissolved in 15 ml of methanol was added. The
aeration rate was fixed at 0.6v/v/m. The stirrer speed was adjusted to 600 rpm, and the dissolved
oxygen concentration was maintained at 45±5 % saturation. The progress of naringenin conver-
sion was monitored by thin layer chromatography (TLC) and high-performance liquid chroma-
tography (HPLC). This procedure was repeated three times. Substrate control sample consisted of
naringenin and a sterile growth medium incubated without a microorganism.
Sample Preparation
Five milliliters of the culture medium was acidified with 1 M HCl to pH 4 and extracted three
times with 7.5 ml of ethyl acetate. The combined extracts were evaporated and the residue
dissolved in methanol and analyzed by TLC and HPLC.
Products Isolation and Analysis
TLC was carried out on Merck silica gel 60 F254 (0.2 mm thick) plates. Compounds were
detected by spraying the plates with 1 % Ce(SO4)2 and 2 % H3[P(Mo3O10)4] in 10 % H2SO4.
HPLC was performed on a Waters 2695 Aliance instrument with a photodiode array detector
Waters 2996 (detection at 290-nm wavelength) using the analytical HPLC column Agilent
ZORBAX Eclipse XDB 5 μm (46×250 mm). Separation conditions: flow rate of 0.8 ml/min;
mobile phase A: acetonitrile; mobile phase B: 0.1 % acetic acid in water. Chromatographic
separation was achieved using the gradient elution: linear gradient of A from 25 to 38 % over
10 min, isocratic elution of A 38 % for 18 min, linear gradient of A from 38 to 25 % over
2 min, and isocratic elution of A 25 % for 6 min.
When the biotransformation was complete, the culture was acidified with 1 M HCl to pH 4
and extracted three times with 0.5 L of ethyl acetate. The combined organic phases were
evaporated and the products separated by column chromatography on Sephadex LH-20 gel
(Pharmacia) using chloroform/methanol (8:2v/v) as eluent. Quantitative analysis of the ethyl
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acetate extract of the biotransformation mixture was performed by means of HPLC, using
calibration curves for the substrate and for all the isolated products.
Nuclear magnetic resonance (NMR) spectra (1H NMR, 13C NMR, DEPT 135°, 1H–1H NMR
(COSY), and 1H–13C NMR (HMQC)) were recorded on a MHz DRX Bruker Avance™ 600
(600MHz) instrument in DMSO-d6 (Sigma-Aldrich). UV spectra were run on a Spectrofotometer
Cintra 303, GBC, in methanol (Merck). Negative-ion electrospray ionization tandem mass
spectrometry (ESI-MS) spectra were measured on a Bruker micrOTOF-Q spectrometer.
Free Radical-Scavenging Activity Assay
Free radical-scavenging activity wasmeasured essentially by themethod proposed by Sharma and
Bhat [49] using 1,1-diphenyl-2-picrylhydrazyl (DPPH, Sigma-Aldrich). Briefly, 1 ml of 0.5 mM
methanolic solution of DPPH radical was added to 2 ml of methanol and 2 ml of methanolic test
samples of different concentrations. Final concentration of DPPH in each sample was 100 μM
(0.5 μmol). The solvents and other chemicals were of analytical grade. The mixtures were shaken
vigorously and left to stand for 30min at room temperature in the dark. The absorbance at 517 nm
by DPPH was measured by UV–vis spectrophotometry. Naringenin was used as a control.
The percentage of inhibition of the DPPH radical by the samples was calculated as follows:
Inhibition %½  ¼ 100 ABSt¼0−ABSt¼30ð Þ
.
ABSt¼0;
where ABSt=0 was the absorbance of DPPH at time 0 and ABSt=30 was the absorbance of
DPPH after 30 min of incubation. Sample concentration providing 50 % of inhibition (IC50)
was calculated from the graph plotting inhibition percentage against compound concentration
in a sample. All measurements were made in triplicates. One-way analysis of variance
(ANOVA) was performed with SPSS. The differences were considered significant at p<0.05
using the post hoc evaluation with Fisher’s least significant difference test.
Results and Discussion
Recently, we reported the ability of the yeast Rhodoorula marina to transform naringenin into
polyhydroxylated products: carthamidin and isocarthamidin [31]. In those studies, the bio-
transformation was carried out in Erlenmeyer flasks, with the maximum initial concentration
Fig. 2 The course of naringenin transformation in the Rhodotorula marina culture (determined by HPLC)
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of naringenin of 300 mg/l. The present research focuses on performing this reaction in a larger
scale, using a bioreactor.
The products of naringenin biotransformation—carthamidin and isocarthamidin—were
unambiguously identified by spectroscopic methods (NMR, UV, and HR ESI-MS).
Figure 2 shows the time course of bioconversion of naringenin run in a 2.0-l batch culture.
To a 24-h-old culture of the dry biomass concentration of 7.4 g/l (Fig. 3), 600 mg of the
substrate (300 mg/l) was added. Both products appeared simultaneously and accumulated in
the reaction mixture at highest rate over 12 h.
Maximum conversion efficiency of carthamidin was 0.31 mg/mg of naringenin and that of
isocarthamidin was 0.47 mg/mg of naringenin. At this stage of the biotransformation, the total
Fig. 3 Growth curve of Rhodotorula marina on 2-l scale in a fermenter
Fig. 4 HPLC elution profile of extract of 12-h biotransformation mixture; N naringenin, C carthamidin, I
isocarthamidin
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concentration of the flavonoids in the bioreactor determined by HPLC (Fig. 4) was found to be
237.3 mg/l (93.3 mg/l for carthamidin, 140.0 mg/l for isocarthamidin, and 4.0 mg/l for
naringenin). The specific production rate for the mixture of carthamidin and isocarthamidin
reached the value of 0.065 g/gl and the maximal yield of 0.399 g/g. Both microbial growth time
and biotransformation time were considerably shorter compared to the cultures cultivated in
shaken Erlenmeyer flasks. In a 24-h-old culture, we obtained the cell dry biomass of 7.43 g/L,
whereas such a value was observed earlier for a 41-h-old culture [31]. Biotransformation time
was also much shorter, as after 12 h in the bioreactor, there was no more naringenin observed,
while in Erlenmeyer flasks, it was present in amount of 83 % of the flavonoid mixture.
In the laboratory scale studies conducted by Xu et al. (2012) using Aspergillus niger as a
biocatalyst, similar conversion of the substrate to both products was observed but at signifi-
cantly lower concentrations. The maximum concentration of isocarthamidin was 21.7 mg/l and
carthamidin 21.5 mg/l, with the initial concentration naringenin equal to 60 mg/l. Another
major advantage of our method is the short reaction time.
The optimal time of cultivation and biotransformation using A. niger was 3–4 days,
whereas a 24-h-old culture of R. marina performed the reaction in 12 h.
Moreover, biotransformations by yeasts are generally simpler and more convenient com-
pared to molds.
The antioxidant activity was checked for the mixture of 12-h biotransformation extract and
for the mixture of carthamidin and isocarthamidin (1:8) obtained after the purification of this
extract. The 2,2′-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging method was applied,
using commercial naringenin as a control. The IC50 values were found as follows: 14.3 mg/l for
the 12-h biotransformation mixture extract, 4.0 mg/l for purified hydroxylated products and
50.1mg/l for naringenin. It was demonstrated that the mixture of carthamidin and isocarthamidin
exhibited 12.5-fold higher DPPH scavenging activity than the substrate—naringenin.
Conclusions
On the basis of our results, we can conclude that biotransformation potential of Rhodotorula
marina can be used in a new industrial approach for improvement of flavanone antioxidant
properties. We are currently working on the use of cheap components of the cultivation
medium for biotransformation involving R. marina.
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